BMYBristol-Myers SquibbRunning, no new patients
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Renal Cell Carcinoma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 437 (final count)
- Started
- Jun 21, 2019
- Main results expected
- Mar 11, 2027
- Fully finished
- Mar 11, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS) by blinded independent central review (BICR)
Measured over: Up to 34 months
Objective response rate (ORR) by BICR
Measured over: Up to 23 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03873402 · record last updated 2026-01-21 · checked 2026-11-09 15:47 UTC